While tumor-targeting mAbs (eg, anti-CD20) require activating FcγR engagement to trigger effector mechanisms,7–9 inhibitory FcγRIIb binding has been demonstrated to optimally deliver agonistic activity for a range of costimulatory mAbs.10–13. The gene discussed is FCGR2A; the disease is neoplasm.